UK Geographic Atrophy Market

UK Geographic Atrophy Market Size

As per the survey report on UK geographic atrophy market, the market is expected to foresee a CAGR value of 27.7% during 2026-2036, and further generate a market size of USD 9.7 billion by the end of 2036. In 2025, the market size was value at USD 1.2 billion revenue.

• The UK geographic atrophy market’s growth is driven by rising healthcare expenditure.
• KDMI analyst’s growth analysis foresees limited availability of treatments as restraint for UK geographic atrophy market.
• In the UK geographic atrophy market, type segment is playing significant role.

UK Geographic Atrophy (GA) Market Analysis

Geographic atrophy (GA) is a serious eye condition. It occurs in people with another eye condition called age-related macular degeneration. The condition is characterized by the progressive, irreversible death of light-sensing cells, and their supporting tissues in the macula. The United Kingdom GA market is experiencing growth driven by increasing prevalence of age-related macular degeneration among the aging population. According to commonslibrary, in 2022, there were approximately 12.7 million people aged 65 or above in the UK. This can further reach 22.1 million people by 2072. Also, geographic atrophy is responsible for nearly 26% of all cases of legal blindness in the UK. The number of AMD cases is projected to grow by 24.4% over the next 10 years. Additionally, technological advancements are contributing to rise in awareness campaigns aimed to educate the public about eye health, which accelerates market expansion.

UK Geographic Atrophy (GA) Market Growth Drivers and Restraints

Growth Drivers

• Increased R&D Investment by Pharmaceutical Companies - Pharmaceutical companies in the UK are significantly increasing their investment in research and development to address unmet medical needs in ophthalmology, including geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD). According to SOCI report, the life sciences foreign direct investment (FDI) into the UK was around 58% lower in 2023, reaching at 795 million euros than in 2017. Also, UK cell and gene therapy companies raised approximately 200 million euros of venture capital in 2023, which enabled to initiate 47 clinical trials in 2024 . This strong R&D ecosystem is expected to expand the geographic atrophy market across the UK.
• Rising Healthcare Expenditure - The UK’s increasing healthcare expenditure is another major factor supporting the growth of the geographic atrophy market. According to kingsfund data, the UK spent nearly 10.9% of GDP on health in 2023. This is higher than pre-COVID-19 pandemic levels. The per capital spending on health was USD 6,747, more than OECD average. Higher healthcare spending enables wider adoption of premium therapies and supports reimbursement for new ophthalmic drugs, thereby contributing to market expansion.
• Rising Demand for Effective Eye Care Solutions - The demand for effective eye care solutions in the UK is growing rapidly, driven by the increasing incidence of age-related eye disorders and increased awareness about vision health. According to Marsha de Cordova, over 2.2 million people in the UK are living with a condition that causes sight loss, which is projected to rise to 4 million people, costing approximately 33.5 billion euros per year. Additionally, the eye care system of the UK caters the needs of over 8 million people annually. Additionally, greater public awareness campaigns and routine eye screening initiatives are encouraging timely intervention, which is boosting the adoption of innovative therapies and expanding the UK geographic atrophy market.

Restraints

• High cost of treatments – A key restraints in the UK geographic atrophy market is the high cost associated with advanced therapies, diagnostic procedures, and long-term disease management. Newly developed treatments often require higher upfront investment in research, development, and clinical trials, which deters small-scale clinics to adopt advanced treatment solutions, thereby limiting market growth.
• Limited availability of curative treatments – Despite of ongoing advancements in ophthalmology, treatment options for geographic atrophy remain limited, with most available therapies focusing on slowing disease progression than restoring lost vision, thereby limiting overall growth of GA market.

UK Geographic Atrophy (GA) Market Segmentation

Our experts at KD Market Insights have segmented the UK geographic atrophy market research report as:

Analyst’s Observation on UK Geographic Atrophy (GA) Market Recent Developments

Over the years, the experts at KD Market Insights have been observing the recent developments associated with UK geographic atrophy market trends. Our expert’s market forecast analysis has recorded the market players adopting plentiful of key strategies including new product launches, mergers & acquisitions, and collaborations.

On February 24,2025, Complement Therapeutics has secured €72 million ($79 million) in Series A financing to accelerate the development of its innovative gene therapy program for geographic atrophySearch disease, a devastating eye condition that leads to blindness. The substantial funding round was headed by Belgian private equity firm Gimv, with co-leadership from existing investor Forbion. 

UK Geographic Atrophy (GA) Market Competitive Landscape

Some of the significant participants who top the UK GA market growth:

• Apellis Pharmaceuticals, Inc.
• Iveric Bio (Astellas Pharma Inc.)
• Novartis AG
• Roche Holding AG (Genentech, Inc.)
• Gyroscope Therapeutics Limited
• Alkeus Pharmaceuticals, Inc.
• Regenerative Patch Technologies LLC
• Stealth BioTherapeutics
• Lineage Cell Therapeutics, Inc.
• Hemera Biosciences (Janssen Pharmaceuticals)